Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $23.8450 (0.34%) ($23.6400 - $24.0500) on Wed. Aug. 26, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.93% (three month average) | RSI | 65 | Latest Price | $23.8450(0.34%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.3% a day on average for past five trading days. | Weekly Trend | TGTX advances 9.5% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(59%) IWO(57%) ARKK(56%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -1.965% in a week (0% probabilities). VIXM(-36%) VXX(-33%) UUP(-18%) DRIV(-4%) TBT(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.965% (StdDev 3.93%) | Hourly BBV | 1.2 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $23.62(0.95%) | 10 Day Moving Average | $22.96(3.85%) | 20 Day Moving Average | $21.52(10.8%) | To recent high | -1.3% | To recent low | 41.9% | Market Cap | $3.02b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |